Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

What Was Tested

In this not phased trial, researchers set out to test NAD+.

This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

It had nine arms (groups): NR via IM injection (experimental), NR via subcutaneous injection (experimental), NR via IV push (experimental), NAD+ via IM injection (active comparator) and NAD+ via subcutaneous injection (active comparator).

The registry classes the interventions as dietary supplement and other.

More on the Plan

The purpose of this work is to explore the tolerability of Niagen®, nicotinamide riboside chloride, a specialized form of vitamin B3, via intramuscular (IM), subcutaneous (SQ), and intravenous-push (IVP) administration, in comparison to NAD+, an active comparator, administered through the same routes.

Who Took Part

The registry lists 70 planned participants were the target.

It was open to people of any sex aged from 40 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Provision of signed and dated informed consent form. Lives within 100 miles of the NRI study site. Any gender, aged 40-65, inclusive. Good general health as evidenced by medical history. BMI 25-34.9 kg/m2.

The full record lists 10 inclusion and 10 exclusion criteria; among the exclusions: current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or parkinson's disease; ANY chronic illness (pre-disease state acceptable); out of range phosphate levels at baseline.

How the Study Was Run

Design: randomized, parallel-group and quadruple-blind.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2024-10-31 with completion listed for 2025-04-30.

It ran at 1 site in United States.

Its stated primary purpose is other.

What Was Measured

Primary outcome: McGill Pain Questionnaire (time frame: 1 minute after injection is complete). Subjective Discomfort (time frame: 1 minute after injection is complete).

It also tracked 3 secondary outcomes, for example C-reactive protein, Sed Rate and plasma viscosity.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 70 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.